Health brief
Drug Pricing Benchmarks, Trial Digital Twins, and Care Access Battles
CMS establishes an international pricing model for Part B drugs as federal authorities overhaul clinical trials and courts enforce care access.
Health
CMS finalized its international drug pricing benchmark but exempted orphan and gene therapies — preserving drugmaker profits while cutting savings to $440M.
BackgroundThe Medicare Part B program pays for costly physician-administered biologics, cancer therapies, and specialty drugs under a statutory average sales price formula. Policymakers have repeatedly attempted to link domestic Medicare reimbursements to lower international prices paid by health systems abroad.
- Launching in January 2027, the mandatory model targets single-source specialty drugs where annual Medicare Part B program spending exceeds $100 million.
- CMS exempted biosimilars, orphan therapies, and cell and gene treatments from the final rule, cutting projected savings from billions down to $440 million.
- Pharmaceutical trade organizations warned the international pricing benchmark will stifle domestic venture investment, threatening the commercialization of complex oncology and autoimmune pipelines.
Health
HHS and ARPA-H launched SURPASS to replace traditional patient control groups with digital twins — aiming to compress multi-year clinical trial timelines.
BackgroundTraditional clinical trials take years to recruit patients, execute protocols, and process regulatory filings, driving the development cost of new pharmaceutical therapies past $2 billion. Federal health agencies have sought computational frameworks to safely compress Phase 2 and 3 timelines.
- SURPASS utilizes real-time adaptive trial platforms and biostatistical machine learning engines to model patient control groups and optimize dosing regimens.
- HHS Secretary Robert F. Kennedy Jr. framed the investment as essential to keep cutting-edge biotechnology testing in the United States rather than China.
- The program funds domestic community clinical trial sites to accelerate diverse patient recruitment for breakthrough rare disease treatments, expanding access beyond academic centers.
Health
The FDA cleared Bristol Myers' Camzyos for pediatric heart patients — delivering the first targeted medical alternative to open-heart surgery for children.
BackgroundObstructive hypertrophic cardiomyopathy causes the heart muscle to thicken excessively, obstructing blood outflow from the left ventricle and causing debilitating chest pain, fatigue, and sudden cardiac arrest. Pediatric treatments were previously limited to non-specific beta-blockers or invasive open-heart surgical septal myectomy.
- The pediatric clearance covers adolescent patients weighing at least 30 kg, backed by Phase 3 trial data showing a 48 mm Hg outflow gradient reduction.
- Camzyos carries an established boxed warning for systolic heart failure and requires monitoring under a standardized Risk Evaluation and Mitigation Strategy program to mitigate dosing risks.
- Cardiologists welcomed the approval as a transformative non-surgical alternative for managing genetic cardiac obstruction in young patients, potentially deferring open-heart procedures for years.
Health
Health
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
